Edition:
India

Deinove SA (ALDEI.PA)

ALDEI.PA on Paris Stock Exchange

0.77EUR
3 Jul 2020
Change (% chg)

€0.00 (+0.52%)
Prev Close
€0.76
Open
€0.76
Day's High
€0.77
Day's Low
€0.75
Volume
15,069
Avg. Vol
179,248
52-wk High
€1.34
52-wk Low
€0.48

Latest Key Developments (Source: Significant Developments)

Deinove: Appoints Alexis Rideau As CEO
Monday, 4 May 2020 

May 4 (Reuters) - DEINOVE SA ::ALEXIS RIDEAU APPOINTED CHIEF EXECUTIVE OFFICER OF DEINOVE WITH THE AMBITION TO STRENGTHEN THE COMPANY'S STRATEGY FOR INNOVATION AND PARTNERSHIPS.APPOINTMENT OF ALEXIS RIDEAU AS CEO, EFFECTIVE MAY 1, 2020.  Full Article

Deinove Announces Enrolment Of First Patient In Phase II Trial Testing Dnv3837 In Clostridioides Difficile Infections
Monday, 27 Jan 2020 

Jan 27 (Reuters) - Deinove SA ::ENROLMENT OF FIRST PATIENT IN PHASE II TRIAL TESTING DNV3837 IN CLOSTRIDIOIDES DIFFICILE INFECTIONS.ENROLMENT OF FIRST PATIENT IN PHASE II TRIAL TESTING DNV3837 IN CLOSTRIDIOIDES DIFFICILE INFECTIONS.TRIAL WILL BE CONDUCTED MAINLY IN 15 CENTERS IN UNITED STATES, IN TWO SUCCESSIVE STAGES: A COHORT OF 10 PATIENTS WITH MODERATE TO SEVERE CDI TREATED WITH DNV3837.FINAL RESULTS OF THIS TRIAL ARE EXPECTED BY END OF 2020..PHASE II TRIAL AIMS TO EVALUATE EFFICACY OF DNV3837 IN PATHOLOGICAL CONDITIONS.  Full Article

Deinove And Avril Complete Development Of Natural Feed Additive
Tuesday, 11 Jun 2019 

June 11 (Reuters) - DEINOVE SA ::DEINOVE AND AVRIL COMPLETING DEVELOPMENT OF A NATURAL FEED ADDITIVE.TWO PARTNERS AIM TO BRING A FIRST INGREDIENT TO MARKET BY END OF 2020.TESTS AIMED AT VALIDATING DOSAGE REQUIRED HAVE CONFIRMED A VERY GOOD EFFICACY OF INGREDIENT.TEAMS ARE WORKING TO DEVELOP A FORMULATION THAT MEETS REGULATORY AND INDUSTRIAL REQUIREMENTS FOR BRINGING A COMMERCIAL INGREDIENT TO MARKET.  Full Article

Deinove & Dow Sign A Collaboration Agreement
Wednesday, 5 Jun 2019 

June 5 (Reuters) - DEINOVE SA ::DEINOVE & DOW SIGN A COLLABORATION AGREEMENT FOR THE DEVELOPMENT OF A NEW COSMETIC ACTIVE INGREDIENT.COMMERCIALIZATION IS PLANNED FOR EARLY 2021.DOW SELECTED EXTRACT BELONGING TO DEINOVE PROPRIETARY STRAINS' BANK TO LAUNCH NEW COSMETIC ACTIVE INGREDIENT FOR SKIN CARE APPLICATIONS.  Full Article

US Department of Defense and Deinove Announce DNV3681 Results
Monday, 20 May 2019 

May 20 (Reuters) - DEINOVE SA ::DNV3681 DEMONSTRATED A SUPERIOR IN VITRO EFFICACY COMPARED TO CIPROFLOXACIN WHICH IS PRODUCT OF REFERENCE WHEN EXPOSED TO BACILLUS ANTHRACIS.DNV3681 IS ACTIVE MOLECULE OF DNV3837, DEVELOPED IN PARALLEL BY DEINOVE AS A POTENTIAL TREATMENT FOR GASTROINTESTINAL INFECTIONS CAUSED BY CLOSTRIDIUM DIFFICILE.  Full Article

Deinove FY Consolidated Group Loss Widens To 8.7 Million Euros
Friday, 29 Mar 2019 

March 28 (Reuters) - DEINOVE SA ::FY CONSOLIDATED GROUP LOSS EUR 8.7 MILLION VERSUS LOSS OF EUR 7.3 MILLION YEAR AGO.FY OPERATING LOSS EUR 10.5 MILLION VERSUS LOSS OF EUR 9.7 MILLION YEAR AGO.FY OPERATING REVENUE EUR 0.8 MILLION VERSUS EUR 0.2 MILLION YEAR AGO.  Full Article

Deinove Prepares Phase II For DNV3837 In Clostridium Difficile Infections
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - DEINOVE SA ::DEINOVE IS PREPARING INITIATION OF PHASE II FOR DNV3837 IN CLOSTRIDIUM DIFFICILE INFECTIONS, WITH A KEY PARTNER.TRIAL IS SCHEDULED TO BEGIN MID-2019.TEST DESIGN HAS BEEN IMPROVED FOR A BETTER ASSESSMENT OF DNV3837 EFFECTIVENESS IN TREATING CLOSTRIDIUM DIFFICILE INFECTIONS,.DEINOVE HAS CHOSEN MEDPACE AS ITS CLINICAL RESEARCH ORGANIZATION (CRO)(1) TO PREPARE AND OVERSEE TRIAL.THIS WILL BE A MULTICENTER TRIAL, TAKING PLACE MOSTLY IN UNITED STATES.  Full Article

Deinove To Market 2nd Proprietary Carotenoid-Based Cosmetic Active Ingredient In 2019
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - DEINOVE SA ::DEINOVE WILL MARKET A 2ND PROPRIETARY CAROTENOID-BASED COSMETIC ACTIVE INGREDIENT IN 2019.THIS ACTIVE INGREDIENT, WHICH TARGETS A DERMOCOSMETIC INDICATION THAT IS ON RISE, WILL BE LAUNCHED IN 2019.FIRST EFFICACY TESTS CARRIED OUT IN ITS LABORATORIES HAVE BEEN PROMISING..  Full Article

Deinove Renews Its Equity Line
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - DEINOVE SA ::DEINOVE CONFIRMS ITS FINANCING OPTIONS BY RENEWING ITS EQUITY LINE.EQUITY LINE FUNDING SET UP IN DECEMBER 2014 EXPIRED.NEW EQUITY LINE, ONCE AGAIN STRUCTURED BY KEPLER CHEUVREUX, ADDS UP TO A MAXIMUM AMOUNT OF EUR 12 MILLION OVER 36 MONTHS..THIS NEW EQUITY LINE CAN BE SUSPENDED OR TERMINATED AT ANY TIME.REMAINING EUR 8 MILLION REMAIN SUBJECTED TO RESOLUTIONS THAT WILL BE PUT TO VOTE OF 2019 GENERAL MEETING..THIS RESERVE FUNDING CAPABILITY WILL REINFORCE DEINOVE'S CASH POSITION(2) AND ALLOW COMPANY TO FINANCE ITS OPERATIONS OVER NEXT TWELVE MONTHS.2,100,000 NEW SHARES ALLOWED TO BE SUBSCRIBED WITHIN SCOPE OF RESOLUTIONS PASSED BY 2018 GENERAL MEETING ADD UP TO APPROXIMATELY EUR 4 MILLION, BASED ON CURRENT STOCK PRICE.THIS NEW PROGRAM GIVES DEINOVE ADDITIONAL FINANCIAL FLEXIBILITY PARTICULARLY IN LIGHT OF UPCOMING START OF PHASE IIA CLINICAL TRIAL OF ITS ANTIBIOTIC CANDIDATE, DNV3837.  Full Article

Deinove To Collaborate With Calibr To Explore Anti-Infectious Potentials Of Its Bacterial Collection
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - DEINOVE SA ::DEINOVE TO COLLABORATE WITH CALIBR TO EXPLORE BROADLY THE ANTI-INFECTIOUS POTENTIALS OF ITS BACTERIAL COLLECTION.  Full Article

BRIEF-Deinove FY Group Net Loss Widens To 10.2 Million Euros

* GROUP NET LOSS FOR 2019 EUR 10.2 MILLION, COMPARED WITH LOSS OF EUR 8.7 MILLION IN 2018, MAINLY DUE TO PROGRESS OF DNV3837 CLINICAL PROGRAM